➤ Patients usually receive initial infusions of IGIV in a hospital or ambulatory care setting, where nurses can provide close supervision and potential infusion complications can be managed safely.
➤ Before beginning infusions, nurses should verify physicians' orders, check for clinical contraindications to IGIV therapy, and assess patients' renal, hepatic, cardiovascular, respiratory, and neurologic functions.
S
ince its introduction in the early 1980s, immune globulin IV (IGIV) therapy has become an important means for treating a variety of disease states manifested by defi cient production of immunoglobulins or by aberrant production of autoantibodies (autoimmune disorders). Among the conditions are primary immune deficiency (PID), idiopathic (or immune) thrombocytopenic purpura (ITP), Kawasaki disease, chronic lymphocytic leukemia (CLL), hematopoietic stem cell transplantation (HSCT), and HIV infection in children. This article discusses the medical indications for IGIV therapy, clinical implications of specifi c IGIV product properties and differences, and practical considerations in IGIV dosage and administration, nursing management, and patient education. Two case reports highlight nurses' role in administering IGIV therapy and monitoring patients for adverse effects.
Immune Function
The body has two major immune response systems: nonspecifi c and specifi c. Nonspecifi c immunity includes barriers (e.g., physical barriers such as skin, chemical barriers such as gastric acid) as well as immune responses such as granulocytic phagocytosis and complement protein activation. Nonspecifi c immunity is essential as the fi rst line of defense against potentially invading pathogens. It is most important for infl ammatory reactions and destruction of bacterial microbes.
Lymphocytes are the essential elements of the specifi c immune response, which targets unique antigenic structures, foreign proteins, viral particles, and transplanted tissue. The two arms of the specifi c immune system are cellular and humoral. Cytokines from T lymphocytes provide protein-specifi c cytotoxicity (i.e., cellular immunity). B lymphocytes provide targeted cell destruction (i.e., humoral immunity) through creation of antibodies, also known as immunoglobulins. The B cells that conduct the humoral immune response may be activated by a direct encounter with an antigen or by T-cell cytokines. In either case, activated B cells evolve into antibody-producing cells known as plasma cells. If a specifi c antigen particle or organism enters the body for a second or subsequent time, a Conclusions: The safety and effectiveness of IGIV therapy depend on selection of an appropriate product, dosage, and infusion rate; patient comorbidities and other risk factors; and patient education and treatment adherence.
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